---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-218240"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2026-05-12T12:08:34+00:00"
generated_at: "2026-05-12T12:13:17.200168+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Kalaris Q1 net loss $10.9M; cash $104.9M; Phase 1b/2 TH103 screening patients

## Summary
- Net loss $10.9M in Q1 2026 vs $10.2M in Q1 2025; R&D expense $7.6M (+27% YoY).
- Cash and securities $104.9M at March 31, 2026, down from $118.0M at December 31, 2025; runway into Q4 2027.
- Patient screening underway in Phase 1b/2 multiple-ascending-dose trial of TH103 for wet AMD; data expected 1H 2027.
- New manufacturing batch completed with process enhancements reducing impurities; Phase 3 initiation on track for end of 2027.

## SEC filing metadata
- accession: 0001193125-26-218240
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2026-05-12T12:08:34+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312526218240/0001193125-26-218240-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312526218240/d24879d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-218240
- JSON: https://secwatch.observer/filing/0001193125-26-218240.json
- Plain text: https://secwatch.observer/filing/0001193125-26-218240.txt

## Key facts
- Earnings Releases
  Kalaris Therapeutics, Inc. reported financial results for quarter ended March 31, 2026.
  - Period: quarter ended March 31, 2026
  - Result: reported results
  source text: Research and Development Expenses : Research and development expenses were $7.6 million for the quarter ended March 31, 2026, compared with $6.0 million for the quarter ended March 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1754068/000119312526218240/0001193125-26-218240-index.htm
- Earnings Releases
  Kalaris Therapeutics, Inc. reported financial results for quarter ended March 31, 2026.
  - Period: quarter ended March 31, 2026
  - Result: reported results
  source text: General and Administrative Expenses : General and administrative expenses were $4.3 million for the quarter ended March 31, 2026, compared with $4.3 million for the quarter ended March 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1754068/000119312526218240/0001193125-26-218240-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.